In previous studies, we found that POF (A combination of oxaliplatin, fluorouracil and
Paclitaxel) regimen appears to be of good efficacy and is well tolerated in patients with
advanced gastric cancer. Apatinib is an orally antiangiogenic agent. It was approved and
launched in China in 2014 as a 3rd-line treatment for patients with advanced gastric cancer.
Therefore, investigators conducted the dose escalation phase I study to explore the safety of
combination of apatinib and POF as first-line treatment for advanced gastric cancer. Now we
are going to start a phase 2 trial with apatinib 500mg + POF as first-line therapy to
investigate the efficacy and safety in the patients with advanced gastric cancer.